Pharmacokinetics of selective estrogen receptor modulators

Clinical Pharmacokinetics
Karla C MorelloM W DeGregorio

Abstract

Selective estrogen receptor modulators (SERMs) are a class of compounds used to treat and prevent breast cancer and osteoporosis. SERMs currently approved for use in patients include tamoxifen, toremifene and raloxifene. These compounds are well tolerated in patients, and the most common adverse effects experienced in patients undergoing SERM therapy include vasomotor symptoms such as hot flashes and vaginal discharge. New SERMs currently under development for use in the treatment and prevention of osteoporosis and breast cancer include ospemifene, a derivative of toremifene, and arzoxifene, a compound very similar in structure to raloxifene. SERMs are administered orally at doses ranging from 20 to 60 mg/day. Tamoxifen and toremifene have a bioavailability of approximately 100%, whereas that of raloxifene is only 2%. SERMs are very highly bound to plasma proteins (>95%). Tamoxifen and toremifene are metabolised by the cytochrome p450 enzyme system, and raloxifene is metabolised by glucuronide conjugation. The terminal elimination half-lives of these drugs range from 27.7 hours to 7 days. The pharmacokinetics of these compounds are affected in hepatically impaired patients, but not in renally impaired patients. SERMs have sever...Continue Reading

Associated Clinical Trials

References

Jan 1, 1990·Cancer Chemotherapy and Pharmacology·V J WiebeM W DeGregorio
Jan 1, 1990·Cancer Chemotherapy and Pharmacology·L Kangas
Jan 1, 1989·Cancer Chemotherapy and Pharmacology·M W DeGregorioW M Holleran
Jan 1, 1984·Pharmacology & Therapeutics·B J Furr, V Craig Jordan
Mar 1, 1982·Acta Pharmacologica Et Toxicologica·N WilkingN O Theve
Jan 1, 1980·Cancer Chemotherapy and Pharmacology·P WilkinsonJ Patterson
Jan 1, 1997·Cancer Chemotherapy and Pharmacology·E A Sotaniemi, M I Anttila
Feb 29, 2000·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·P J MeunierM Draper

Citations

Jul 25, 2009·Nature Reviews. Cancer·Janelle M HoskinsHoward L McLeod
Feb 21, 2007·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Y F LiJ J Kavanagh
Jun 21, 2013·Science Translational Medicine·Lisa M JohansenGene G Olinger
Jun 3, 2009·Antimicrobial Agents and Chemotherapy·Kristy DolanDamian J Krysan
Aug 10, 2010·Core Evidence·Luigi GennariRanuccio Nuti
Nov 10, 2009·Therapeutics and Clinical Risk Management·E Michael Lewiecki
Jul 25, 2013·International Journal of Molecular Sciences·Miia TurpeinenMika Scheinin
Jun 28, 2014·International Journal of Nanomedicine·Márcia Camponogara FontanaRuy Carlos Ruver Beck
Jun 15, 2014·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Nicolas WidmerAlain Astier
Dec 17, 2008·Women's Health·Mohamed Fm Mitwally
Aug 19, 2006·Expert Opinion on Investigational Drugs·Luigi GennariRanuccio Nuti
May 27, 2009·Expert Opinion on Investigational Drugs·Luigi GennariRanuccio Nuti
Feb 1, 2011·Expert Opinion on Drug Discovery·Luigi GennariRanuccio Nuti
Jul 25, 2006·Expert Opinion on Drug Metabolism & Toxicology·V Hayden ThomasAyman El-Kattan
Mar 1, 2006·Expert Opinion on Investigational Drugs·Samir S TanejaKaren A Veverka
Jan 15, 2014·Journal of the American Chemical Society·Grace Y Stokes, John C Conboy
May 19, 2006·Journal of Clinical Pharmacology·R J FountaineMark J Gardner
Jan 20, 2007·Biomedical Chromatography : BMC·Zhaoyong YangYueqin Zhang
Jan 7, 2006·Journal of Clinical Pharmacology·Mark J GardnerAshley Milton
Jul 22, 2008·Medicinal Research Reviews·George G ChenGary Mk Tse
Mar 8, 2012·Journal of Biomedical Materials Research. Part a·A MartínezM D Blanco
Jul 16, 2013·Biopharmaceutics & Drug Disposition·Terhi LehtinenMika Scheinin
Jul 1, 2014·Clinical Pharmacology in Drug Development·William E McKeandArkadi A Chines
Sep 13, 2005·The Journal of Steroid Biochemistry and Molecular Biology·Gregory T WurzM W DeGregorio
Nov 4, 2008·International Journal of Pharmaceutics·Ae Ra KimBeom-Jin Lee
Mar 2, 2012·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Heng-Keang LimDavid C Evans
Jul 6, 2011·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Juhyun KimKaren A Veverka
Mar 19, 2013·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Yuki KokawaNobumitsu Hanioka
Aug 16, 2013·Reproductive Sciences·Sarah L Berga
Jan 25, 2017·Journal of Medicinal Chemistry·Rui XiongGregory R J Thatcher
Aug 29, 2014·Arquivos brasileiros de endocrinologia e metabologia·Guilherme Alcantara Cunha LimaMaria Lucia Fleiuss Farias
Jul 10, 2004·Menopause : the Journal of the North American Menopause Society·Pilar J OviedoAntonio Cano

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Hereditary Sensory Autonomic Neuropathy

Hereditary Sensory Autonomic Neuropathies are a group of inherited neurodegenerative disorders characterized clinically by loss of sensation and autonomic dysfunction. Here is the latest research on these neuropathies.

Glut1 Deficiency

Glut1 deficiency, an autosomal dominant, genetic metabolic disorder associated with a deficiency of GLUT1, the protein that transports glucose across the blood brain barrier, is characterized by mental and motor developmental delays and infantile seizures. Follow the latest research on Glut1 deficiency with this feed.

Regulation of Vocal-Motor Plasticity

Dopaminergic projections to the basal ganglia and nucleus accumbens shape the learning and plasticity of motivated behaviors across species including the regulation of vocal-motor plasticity and performance in songbirds. Discover the latest research on the regulation of vocal-motor plasticity here.

Neural Activity: Imaging

Imaging of neural activity in vivo has developed rapidly recently with the advancement of fluorescence microscopy, including new applications using miniaturized microscopes (miniscopes). This feed follows the progress in this growing field.

Nodding Syndrome

Nodding Syndrome is a neurological and epileptiform disorder characterized by psychomotor, mental, and growth retardation. Discover the latest research on Nodding Syndrome here.

LRRK2 & Microtubules

Mutations in the LRRK2 gene are risk-factors for developing Parkinson’s disease (PD). LRRK2 mutations in PD have been shown to enhance its association with microtubules. Here is the latest research.